CN1872035A - Medication doe treating bronchitis, and preparation method - Google Patents
Medication doe treating bronchitis, and preparation method Download PDFInfo
- Publication number
- CN1872035A CN1872035A CN 200510013617 CN200510013617A CN1872035A CN 1872035 A CN1872035 A CN 1872035A CN 200510013617 CN200510013617 CN 200510013617 CN 200510013617 A CN200510013617 A CN 200510013617A CN 1872035 A CN1872035 A CN 1872035A
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- medicine
- xylitol
- starch
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 90
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 35
- 229940079593 drug Drugs 0.000 title claims description 27
- 239000006187 pill Substances 0.000 claims abstract description 87
- 239000002671 adjuvant Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 59
- HPPWMWCITPGPKK-UHFFFAOYSA-M sodium;1-hydroxy-3-oxododecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCC(=O)CC(O)S([O-])(=O)=O HPPWMWCITPGPKK-UHFFFAOYSA-M 0.000 claims description 58
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 44
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 44
- 239000000811 xylitol Substances 0.000 claims description 44
- 235000010447 xylitol Nutrition 0.000 claims description 44
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 44
- 229960002675 xylitol Drugs 0.000 claims description 44
- 238000002156 mixing Methods 0.000 claims description 34
- 239000000758 substrate Substances 0.000 claims description 31
- 229920002472 Starch Polymers 0.000 claims description 30
- 239000008107 starch Substances 0.000 claims description 30
- 235000019698 starch Nutrition 0.000 claims description 30
- 238000009413 insulation Methods 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 238000002844 melting Methods 0.000 claims description 22
- 230000008018 melting Effects 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 21
- 239000002826 coolant Substances 0.000 claims description 21
- 239000008101 lactose Substances 0.000 claims description 21
- 229920002545 silicone oil Polymers 0.000 claims description 18
- 235000010489 acacia gum Nutrition 0.000 claims description 17
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 17
- 229940057995 liquid paraffin Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 19
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 5
- 239000003292 glue Substances 0.000 description 20
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 19
- YHFXJKYHUWPWSJ-UHFFFAOYSA-L [Na+].[Na+].OS([O-])=O.OS([O-])=O Chemical compound [Na+].[Na+].OS([O-])=O.OS([O-])=O YHFXJKYHUWPWSJ-UHFFFAOYSA-L 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 239000008503 houttuyninum Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 206010006458 Bronchitis chronic Diseases 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- 208000007451 chronic bronchitis Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000006225 natural substrate Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- FKNXQNWAXFXVNW-WBMJQRKESA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@H](O)[C@H](NC(C)C)CC FKNXQNWAXFXVNW-WBMJQRKESA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- SSMSBSWKLKKXGG-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-isopropylaminoethanol Chemical compound CC(C)NCC(O)C1=CC=CC=C1Cl SSMSBSWKLKKXGG-UHFFFAOYSA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VATCAOIQZROKKT-UHFFFAOYSA-L S(=O)([O-])S(=O)[O-].[Na+].C(CCCCCCCCC)(=O)CC=O.[Na+] Chemical compound S(=O)([O-])S(=O)[O-].[Na+].C(CCCCCCCCC)(=O)CC=O.[Na+] VATCAOIQZROKKT-UHFFFAOYSA-L 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 229950011462 clorprenaline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A dripping pill of the medicine to treat bronchitis for treating bronchitis features high natural level and safety and low toxic by-effect. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to field of medicaments, particularly, relating to Chinese medicine is the bronchitic pharmaceutical preparation of a kind of treatment that raw material is made.
Background technology
Bronchitis is a common clinical, frequently-occurring disease, and clinical serves as main performance with cough, expectoration, dyspnea with rapid and short breath, can be divided into two kinds of acute bronchitis, chronic bronchitiss according to its course of disease length.Acute tracheitis is the infection by virus, antibacterial, physics, chemical stimulation, and factor such as allergy causes the acute inflammation of trachea and bronchus mucosa, it is the commonly encountered diseases of respiratory system, be mainly in cold season, clinical with cough, to cough up phlegm is primary symptom, with fever with aversion to cold, disease such as headache, nasal obstruction, pharyngalgia, limbs are miserable.Chronic bronchitis is called for short chronic bronchitis, is meant the chronic nonspecific inflammation of trachea, bronchial mucosa and surrounding tissue, clinically with cough, expectoration or with panting and the chronic process of outbreak repeatedly is a feature.According to cough, expectoration or with panting, annual morbidity continues three months, continuous 2 years or more than, and when getting rid of other heart and lung diseases, diagnosable is chronic bronchitis.The chronic bronchitis delay is difficult, easily causes emphysema, pulmonary heart disease, so chronic bronchitis is bigger than the hazardness of acute bronchitis, it is more difficult to treat.
At present mostly the Western medicine medicine that is used for the treatment of the chronic bronchial pharynx is symptomatic treatment, and side effect is bigger, as Fa Site: can occur one after taking medicine and cross property mouth, pharyngeal numb sensation, untoward reaction such as weak, dizzy, epigastric discomfort and erythra are still arranged in addition; Terbutaline: side effect such as small number of patients is taken can drowsiness, cardiopalmus, headache, xerostomia, finger are trembled, the careful usefulness of hypertension, coronary heart disease, hyperthyroidism, diabetes and anemia of pregnant woman; Yi Tanning: hypertension, coronary heart disease, hyperthyroidism, the careful usefulness of diabetes, share with sympathomimetic and can increase the weight of side effect; As seen Slow-release Theopylline feels sick or slight gastrointestinal upset, and theophylline class allergy sufferers is forbidden; Maxivent, Meptin, diprophylline, clorprenaline hydrochloride, bricasol, breathe heavily happy peaceful, Meptin, Maxivent, terbutaline atomized soln etc. in various degree side effect is also all arranged.The treatment by Chinese herbs chronic bronchitis mostly is decoction, syrup, pill etc., and onset is slow, and uncertain therapeutic efficacy is fixed, and it is bigger that curative effect is influenced by extraneous factor.Sodium Houttuyfonate, chemistry decanoylacetaldehyde sodium hydrosulfite by name is the synthetics identical with the active ingredient decanoylacetaldehyde of natural Herba Houttuyniae, also is that China's initiative is used for clinical antibiosis anti-inflammatory drug.Clinical infantile pneumonia, senile chronic bronchitis, the adnexitis etc. of being used for.May 16 2003 applying date, application number 03117003.X, denomination of invention is: the patent documentation of houttuynine sodium bisulfite sodium dropping balls and preparation method thereof has been introduced a kind of preparation that utilizes Sodium Houttuyfonate to make drop pill, though said preparation has overcome the slow characteristics of drug effect, the adjuvant of this drug use is a chemical adjuvant.The synthetic chemical substance that modern medicine is commonly used has spreaded all over each corner of human lives, chemical synthetic drug becomes the main flow of medicine, yet, appearance along with multiple difficult serious symptom miscellaneous diseases, western medical treatment presents imperfect, the human lives and the healthy reality and the up-to-date successes achieved in research have all proposed query to this situation, particularly along with the continuous appearance of chemical drugs toxic and side effects, the change of spectrum of disease and conversion of medical, make modern medicine be subjected to unprecedented challenge, and people also place hope in the application and development of traditional medicine on gradually.Advocate back to nature, pay attention to plant amedica use, hanker after traditional remedies, the trend of advocating natural drug forms, making full use of natural materials is human best selections.
At present, in the world, natural drug all has certain market, along with people increasing and the aging of population to the health requirements level of understanding, sub-health stateization, people thirst for back to nature more, the problem of utilize the high Drug therapy of pure natural degree, preventing some chemical synthetic drugs cann't be solved, so the application extension of natural plant exceeds the background of its original traditional national culture.From natural drug, seek the little and inexpensive medicine of side effect and become the target that countries in the world pharmaceutical manufacturer is chased.The European Community has carried out unified legislation to medical herbs, state medical herbs status such as Canada and Australia have legalized, U.S. government has also drafted the plant amedica management method, the compound recipe mix preparation that begins to accept natural drug is as curative, and these provide good international environment for Chinese medicine enters international medical market as curative.On the other hand, along with the quickening of global economic integration progress, particularly China becomes a full member of WTO, and Chinese Medicine market incorporates the breadth and depth of international medical big market and will further aggravate.Face the enormous impact of Asian countries's traditional medicine product such as the keen competition of powerful transnational medical group and Japan, Korea S, India, Thailand and European countries' plant amedica such as Germany, France, numerous products that China's Chinese medicine produces are owing to still can not meet the standard of international medical market and requirement and being kept outside of the door.
Expansion and human back to nature requirement along with the market global range, use the low medicine of toxic and side effects, especially pure natural medical more and more becomes people's first-selection, dropping pill formulation be a kind of have efficient, quick-acting new medicine preparations, it has overcome the shortcoming and deficiency of Chinese medicine preparation in the past, but present dropping pill formulation generally faces following problem: 1, drop pill adjuvant pure natural degree is not high: at present, drop pill substrate adjuvant mostly is synthetic, natural degree is lower, the searching of new alternative substrate adjuvant, the searching of the alternative substrate adjuvant that particularly natural degree is high and preparation technology thereof determine, it is again very difficult thing, because the required preparation condition of at present common possible natural substrates adjuvant succedaneum is very harsh, it all is to influence the key that drop pill prepares molding that adjuvant temperature and drop pill thereof drip the system condition.The too high then viscosity of adjuvant melt temperature is low, and poor plasticity is though the adjuvant melt temperature is crossed lowplastcity by force, but drop pill has shortcomings such as easily sticking ball, distortion, therefore, seek pure natural degree height, and the adjuvant that is suitable for substituting existing drop pill substrate is a very job of hardships.2, the drop pill outlet encounters problems: along with expanding economy, more and more internationalize in market, China is also just making great efforts to adapt to this trend, present Chinese medicine dripping pills preparation as health food, successful export to many countries, but also face many problems at present, because different countries is different to the approval of the selected adjuvant of Chinese medicine dropping pill formulation, especially industrial flourishing Europe, more strict to food adjuvant and medical auxiliary materials, and as the selected chemosynthesis adjuvant (as Polyethylene Glycol) of the dropping pill formulation of health food outlet not in the catalogue of some national food additive, it is very unfavorable that this moves towards the international market to the Chinese medicine dropping pill formulation, becomes the stumbling-block that Chinese medicine enters the international market, therefore, seek the new of one or more, can be particularly important, also very urgent for the substrate adjuvant that the international market is accepted.3, the shortcoming of mouthfeel and onset speed: the mouthfeel of Chinese medicine and preparation thereof is relatively poor to be the big characteristics of one, people when taking some drugs to the frightened of disagreeable taste that medicine had even be better than fear far away to disease, What is more, some patients are because can not overcome the poor taste of Chinese medicine or its preparation or abnormal smells from the patient and abandon the treatment of Chinese medicine, though can improve mouthfeel as medicine being made capsule or sugar coated tablet, reducing stimulates, but disintegration rate prolongs, be unfavorable for the rapid onset of medicine, to some disease, particularly need the disease of the rapid onset of medicine inapplicable.4, the preparation process difficulty of drop pill suitability for industrialized production: in the replacement process of dropping pill formulation adjuvant, determining of the preparation process of its suitability for industrialized production is very difficult something, as the ratio of the melt temperature of substrate adjuvant, the proportioning of dripping system temperature, adjuvant and medicine, dropper bore, condensing agent etc. all are the factors that influence drop pill, therefore, the replacement of substrate and to be suitable for suitability for industrialized production be a job consuming time, as to expend substantial contribution.
In order to change drop pill substrate adjuvant for a long time based on the situation of chemosynthesis adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and can not satisfy more and more that people require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect; Also can solve some problems that Chinese medicine preparation, particularly dropping pill formulation are run in exit procedure, strengthen the competitiveness of international market; The present invention has invented the pure Chinese medicine dripping pills preparation that a kind of toxic and side effects is low, evident in efficacy, moderate, adapt to industrialized great production by a large amount of tests and the research of preparation process.
Summary of the invention
The purpose of this invention is to provide a kind of bronchitic medicine of treatment with the preparation of new type natural substrate adjuvant.
Another object of the present invention provides a kind of preparation method for the treatment of bronchitis pharmaceutical preparation.
The selected substrate adjuvant of the present invention is resulting by a large amount of tests, it is little to have molecular weight, soluble in water, and molten diffusing speed is faster, pure natural degree height, toxic and side effects is low, and can reduce the medicine irritation abnormal smells from the patient, has the oral cavity of improvement acid-base value during the buccal of oral cavity, improve the characteristics of oral cavity smell, the used substrate adjuvant of the present invention is the agent of food sedan-chair flavor, takes that mouthfeel is good, the acceptant characteristics of patient, is the direction of following substrate adjuvant development.
The consumption of drug component of the present invention and the selection of adjuvant thereof also grope to sum up to draw through the inventor in a large number, this medicine is formed and is comprised: Sodium Houttuyfonate, appropriate amount of auxiliary materials, wherein adjuvant comprises filler and plasticity substrate, filler adjuvant wherein is selected from the natural adjuvant of following one or more plant origins: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose;
The adjuvant of preferred drug component of the present invention is following one or more the natural adjuvant of plant origin for the filler adjuvant is selected from: xylitol, lactose; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum;
Best substrate adjuvant of the present invention is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
Adjuvant is 1: 0.1～1: 1 with the ratio of the weight of Sodium Houttuyfonate in the pharmaceutical composition of the present invention;
Adjuvant is 1: 0.1～1: 0.6 with the ratio of the weight of Sodium Houttuyfonate in the preferred pharmaceutical composition of the present invention;
Adjuvant is 1: 0.2～1: 0.4 with the ratio of the weight of Sodium Houttuyfonate in the best pharmaceutical composition of the present invention.
Medicine mesostroma adjuvant of the present invention and amount of drug are than being the scope that allows on the galenic pharmacy, and medicine described here can be that crude drug also can be the effective ingredient extract.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method; make common any preparation at present; but, preferably adopt following method to be prepared into dropping pill formulation, but this can not limit protection scope of the present invention in order to make each crude drug of this medicine bring into play drug effect better.
The preparation method of medicine of the present invention is as follows:
(a) get Sodium Houttuyfonate, adjuvant is standby;
(b) in appropriate amount of auxiliary materials, add Sodium Houttuyfonate, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Further preferred manufacturing procedure is: the mixture heated melt temperature is 60～85 ℃ in the step (b), mixing time is 10～30 minutes, dripping the system temperature and be 60～85 ℃, dropper bore is 1.1～3.5 millimeters, and condensing agent is 0～18 ℃ liquid paraffin or a methyl-silicone oil.
Best preparation method is: the mixture heated melt temperature is 64 ℃ in the step (b), and dripping a system temperature and be 64 ℃, dropper bore is 1.2～2.5 millimeters, and condensing agent is 0 ℃ a methyl-silicone oil.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 time, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
The drop pill that the present invention is prepared, conventional drop pill advantage is simple as preparing except having, steady quality, can make liquid medicine solidification, convenient drug administration, efficient, quick-acting, its biggest advantage is:
1, the selected adjuvant pure natural of the present invention degree height: the substrate adjuvant that employed substrate adjuvant derives from natural plants or originates based on natural plants among the present invention, selected substrate adjuvant is xylitol and starch or lactose and starch or xylitol and arabic gum, this substrate adjuvant has pure natural degree height, toxic and side effects is low, mouthfeel is good, dissolve scattered time limit is short, rapid-action, it is a kind of new medium adjuvant, can be used for substituting present chemosynthesis substrate adjuvant, the drop pill made from this kind adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and more and more can not satisfy people and require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect.
2, some problems in the outlet of solution Chinese medicine: medicine of the present invention also can solve Chinese medicine preparation, some problems of in exit procedure, being run into of dropping pill formulation particularly, solve because different countries, especially the European countries of industry prosperity are to the difference identification of the selected adjuvant of Chinese medicine dropping pill formulation, overcome as the selected adjuvant Polyethylene Glycol of the dropping pill formulation of the health food outlet defective in some national food additive catalogue not, improve the Chinese medicine dripping pills preparation and move towards the international market, strengthen the competitiveness of international market.
3, solve the relatively poor problem of drop pill taste and further improve drug effect speed (dissolve scattered time limit): the medicinal dropping ball made from this kind substrate adjuvant of the present invention, can improve Chinese medicine preparation, the particularly present not good shortcoming of dropping pill formulation taste, improve mouthfeel, more easy for patients to accept, and the drop pill that adopts the selected adjuvant of medicine of the present invention to make has shorter dissolve scattered time limit, making drug effect faster, is that bronchitic medicine is treated in a kind of onset faster.
4, higher safety and solve some problems in the drop pill storage process: the selected substrate of the present invention is not only additive, nutrient commonly used in the food industry, and can do medicinal, but do not see that it uses as the drug matrices adjuvant, therefore, with regard to substrate, be perfectly safe, have no side effect, a large amount of evidences, the drop pill that this adjuvant is made can reduce effective ingredient separating out in storage process, the sticking ball of drop pill, easy shortcomings such as moisture absorption deliquescing, but the big production of suitability for industrialized.
The present invention is under instruction of Chinese Medicine theory, preparation technology's test that process is a large amount of and pharmacology, the resulting preparation of pharmacodynamics test.The present invention is evident in efficacy, has relieving cough and expelling phlegm, and the effect of relievining asthma is used for the treatment of chronic bronchitis clinically.Reasonable recipe of the present invention, poisonous side effect of medicine is low, overcome that western medicine chronic bronchitis toxic and side effects is big, expense is high, the Chinese medicine curative effect is low, flavour of a drug are many, the shortcoming of incompatibility large-scale production, is a kind of economy, material benefit, the definite bronchitic medicine of treatment of curative effect.
In order to understand the present invention better, the drop pill made from the new substrate of the present invention (prepares according to the embodiment of the invention 1 method below, hereinafter to be referred as the neo-houttuyninum sodium dropping balls) with test explanation advantages of the present invention such as the dissolve scattered time limit of the drop pill made for the substrate adjuvant with the Polyethylene Glycol (according to application number is the patent documentation embodiment 1 method preparation of 03117003.X, hereinafter to be referred as old houttuynine sodium bisulfite sodium dropping balls), drop pill soft durometer, the sticking ball of drop pill.
Test example 1: dissolve scattered time limit, weight differential contrast experiment's example
In vitro tests
The present invention and old houttuynine sodium bisulfite sodium dropping balls compare, and by measuring dissolve scattered time limit, investigate its good releasing effect; By measuring indexs such as the ball method of double differences is different, whether ripe, whether be fit to suitability for industrialized production if investigating its preparation technology.
1. test medication: neo-houttuyninum sodium dropping balls, old houttuynine sodium bisulfite sodium dropping balls.
2. method and result:
Dissolve scattered time limit: by " method is measured under this item of Chinese pharmacopoeia; The ball method of double differences is different: by " method is measured under this item of Chinese pharmacopoeia.Result of the test sees Table 1.
Three batches of neo-houttuyninum sodium dropping balls of table 1 and old houttuynine sodium bisulfite sodium dropping balls dissolve scattered time limit, weight differential are relatively
| 0 month | January | February | March | June | December | 18 months | ||
| 1 batch | Criterion | The result | ||||||
| Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | |
| Dissolve scattered time limit (newly) (old) | 3′15″ 4′39″ | 3′15″ 4′40″ | 3′17″ 4′41″ | 3′19″ 4′44″ | 3′22″ 4′44″ | 3′25″ 4′42″ | 3′24″ 4′43″ | |
| 2 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (old) | 3′16″ 4′40″ | 3′17″ 4′41″ | 3′16″ 4′41″ | 3′20″ 4′42″ | 3′24″ 4′42″ | 3′24″ 4′44″ | 3′24″ 4′43″ | |
| 3 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (old) | 3′14″ 4′39″ | 3′14″ 4′41″ | 3′16″ 4′41″ | 3′19″ 4′42″ | 3′22″ 4′43″ | 3′25″ 4′41″ | 3′25″ 4′41″ | |
Above-mentioned experimental data shows that the older houttuynine sodium bisulfite sodium dropping balls of the dissolve scattered time limit of neo-houttuyninum sodium dropping balls is few, and the ball method of double differences of the houttuynine sodium bisulfite sodium dropping balls that new and old substrate is made is different to be controlled in the pharmacopeia prescribed limit.The result of the test explanation, the houttuynine sodium bisulfite sodium dropping balls that the new medium adjuvant is made is more conducive to medicine and plays a role in the shortest time, different all being controlled in the pharmacopeia prescribed limit of new, the old houttuynine sodium bisulfite sodium dropping balls ball method of double differences, but suitability for industrialized production.
Test example 2: the comparative observation of neo-houttuyninum sodium dropping balls and old houttuynine sodium bisulfite sodium dropping balls soft durometer, the sticking ball of drop pill
Compare by neo-houttuyninum sodium dropping balls and old houttuynine sodium bisulfite sodium dropping balls, measure indexs such as above-mentioned, investigate its effect.
1. test medication: neo-houttuyninum sodium dropping balls; Old houttuynine sodium bisulfite sodium dropping balls prepares according to document.
2. method and result:
Get each three batches of neo-houttuyninum sodium dropping balls and old houttuynine sodium bisulfite sodium dropping balls, be loaded in the porcelain vase respectively, and use the bottle stopper good seal.Putting it into the bottom has in the exsiccator of saturated Nacl (humidity 75%) solution, exsiccator is put into 40 ℃ of drying baker of constant temperature again, and timing sampling is observed situations such as drop pill soft durometer, the sticking ball of drop pill, the results are shown in Table 2.1, table 2.2.
Three batches of old houttuynine sodium bisulfite sodium dropping balls reserved sample observings of table 2.1 relatively
| 0 month | January | February | March | June | December | 18 months |
| 1 batch | Criterion | The result | ||||||
| Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly | |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 2 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 3 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
Table 2.2: three batches of neo-houttuyninum sodium dropping balls and old houttuynine sodium bisulfite sodium dropping balls character observation are relatively
| 0 month | January | February | March | June | December | 18 months | ||
| Criterion | The result | |||||||
| 1 batch | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | Hard slightly (old) be hard (newly) slightly | |
| 2 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
| 3 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
Table 2.1,2.2 test data show that neo-houttuyninum sodium dropping balls soft durometer changes similar to old houttuynine sodium bisulfite sodium dropping balls, strong slightly; The neo-houttuyninum sodium dropping balls glues the ball variation, firmness change is similar to old houttuynine sodium bisulfite sodium dropping balls.The result of the test explanation, the sticking ball of new, old houttuynine sodium bisulfite sodium dropping balls changes, firmness change is similar, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
The specific embodiment
Embodiment 1
(a) get Sodium Houttuyfonate 5.8g, xylitol 19.6g, starch 6.7g is standby;
(b) get xylitol and starch mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 2
(a) get Sodium Houttuyfonate 2.0g, lactose 17.8g, starch 4.2g is standby;
(b) get lactose and starch mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 3
(a) get Sodium Houttuyfonate 4.0g, xylitol 25.9g, arabic gum 7.1g is standby;
(b) get xylitol and arabic gum mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 4
(a) get Sodium Houttuyfonate 1.5g, xylitol 28.0g, xanthan gum 2.0g is standby;
(b) get xylitol and xanthan gum mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 45～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～70 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in-10～10 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 5
(a) get Sodium Houttuyfonate 2.5g, xylitol 16.5g, starch 7.0g is standby;
(b) get xylitol and starch mix homogeneously, add above-mentioned Sodium Houttuyfonate, mixture stirs at 45～115 ℃ of heating and meltings, and mixing time is 1～30 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splashes in-20～25 ℃ the vegetable oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 6
(a) get Sodium Houttuyfonate 1.5g, erythritol 29.5g is standby;
(b) get erythritol and add above-mentioned Sodium Houttuyfonate, mixture is at 55～75 ℃ of heating and meltings, stir, mixing time is 5～12 minutes, and insulation is 1.20～3.0 millimeters at 55～75 ℃ of temperature following system, dropper bore, splash in 0～15 ℃ the liquid paraffin, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly
Embodiment 7
(a) get Sodium Houttuyfonate 3.0g, xylitol 24.0g, Lac 6.0g is standby;
(b) get xylitol and Lac mixing mixing, add above-mentioned Sodium Houttuyfonate, mixture stirs at 45～115 ℃ of heating and meltings, mixing time is 5～20 minutes, and insulation is dripped system 58～70 ℃ of insulations, splash in 12 ℃ of liquid paraffin, make 1000 drop pill of drop pill, promptly.
Embodiment 8
(a) get Sodium Houttuyfonate 4.0g, xylitol 19.9g, starch 4.1g is standby;
(b) get xylitol and starch mix homogeneously, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～75 ℃ of heating and meltings, and mixing time is 10～60 minutes, insulation, at 55～65 ℃ of temperature following system, dropper bore is 1.0～3.5 millimeters, splashes in-20～25 ℃ the vegetable oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 9
(a) get Sodium Houttuyfonate 6.5g, lactose 16.6g, starch 3.4g is standby;
(b) get mixing of lactose and starch, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 10
(a) get Sodium Houttuyfonate 7.0g, xylitol 16.5g, arabic gum 15.5g is standby;
(b) get the mixing mixing of xylitol and arabic gum, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 11
(a) get Sodium Houttuyfonate 9.5g, xylitol 18.0g, trehalose 2.0g is standby;
(b) get xylitol and trehalose mixing mixing, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.21～3.5 millimeters, splashes in 0～15 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 12
(a) get Sodium Houttuyfonate 8.0g, xylitol 26.6g, tragakanta 3.4g is standby;
(b) get xylitol and tragakanta mix homogeneously, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～20 minutes, insulation, at 60～75 ℃ of temperature following system, dropper bore is 1.5～3.5 millimeters, splashes in 10～18 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 13
(a) get Sodium Houttuyfonate 7.5g, lactose 24.0g, xanthan gum 6.0g is standby;
(b) get lactose and xanthan gum mix homogeneously, add above-mentioned Sodium Houttuyfonate, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 62～67 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 4 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 14
(a) get Sodium Houttuyfonate 15.5g, xylitol 18.5g, arabic gum 3.5g is standby;
(b) get xylitol and arabic gum mix homogeneously, add above-mentioned Sodium Houttuyfonate, mixture stirs at 55～85 ℃ of heating and meltings, and mixing time is 5～30 minutes, insulation, at 58～68 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 15
(a) get Sodium Houttuyfonate 6.0g, lactose 37.0g, tragakanta 9.0g is standby;
(b) getting lactose and tragakanta mixes, add above-mentioned Sodium Houttuyfonate, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 16
(a) get Sodium Houttuyfonate 7.0g, xylitol 26.0g, Furcellaran 4.0g is standby;
(b) get xylitol and Furcellaran mixing, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 62～66 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 17
(a) get Sodium Houttuyfonate 15g, sorbitol 25g, tragakanta 11.5g is standby;
(b) get sorbitol and tragakanta mixing, add above-mentioned Sodium Houttuyfonate and fully mix, make 100 by method for preparing tablet thereof, promptly.
Embodiment 18
(a) get Sodium Houttuyfonate 10.5g, xylitol 14.5g, xanthan gum 8.0g is standby;
(b) get xylitol and xanthan gum mixing, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 15～25 minutes, insulation, at 62～66 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0～15 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 19
(a) get Sodium Houttuyfonate 1g, xylitol 183.3g, starch 16.7g is standby;
(b) get xylitol and starch mix homogeneously, add above-mentioned Sodium Houttuyfonate and fully mix, make 10000 capsules, promptly.
Embodiment 20
(a) get Sodium Houttuyfonate 0.5g, xylitol 13.3g, starch 6.7g is standby;
(b) get xylitol and starch mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 75 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 75 ℃ of temperature following system, dropper bore is 1.25～2.5 millimeters, splashes in 5 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 21
(a) get Sodium Houttuyfonate 0.5g, xylitol 15g, arabic gum 5g is standby;
(b) get xylitol and arabic gum mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 22
(a) get Sodium Houttuyfonate 0.5g, lactose 17g, starch 3g is standby;
(b) get lactose and starch mix homogeneously, adding above-mentioned Sodium Houttuyfonate fully mixes, mixture stirs at 80 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.25～2.5 millimeters, splashes in 5 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Claims (9)
1, the bronchitic medicine of a kind of treatment, it is characterized in that this medicine composition comprises: Sodium Houttuyfonate, appropriate amount of auxiliary materials, wherein adjuvant comprises filler and plasticity substrate, filler adjuvant wherein is selected from the natural adjuvant of following one or more plant origins: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
2, the bronchitic medicine of treatment as claimed in claim 1 is characterized in that wherein filler adjuvant is selected from following one or more the natural adjuvant of plant origin: xylitol, lactose; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum.
3, the bronchitic medicine of treatment as claimed in claim 2 is characterized in that described adjuvant is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Perhaps be lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Perhaps be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
4, the bronchitic medicine of treatment as claimed in claim 1 or 2 is characterized in that the adjuvant and the ratio of the weight of Sodium Houttuyfonate are 1: 0.1～1: 1.
5, the bronchitic medicine of treatment as claimed in claim 1 or 2, it is characterized in that adjuvant and Sodium Houttuyfonate the ratio of weight be 1: 0.1～1: 0.6.
6, the bronchitic medicine of treatment as claimed in claim 1 or 2, it is characterized in that adjuvant and Sodium Houttuyfonate the ratio of weight be 1: 0.2～1: 0.4.
7, a kind of preparation method for the treatment of the bronchitis medicine comprises the steps:
(a) get Sodium Houttuyfonate, adjuvant is standby;
(b) in appropriate amount of auxiliary materials, add Sodium Houttuyfonate, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
8, the preparation method of treatment bronchitis medicine as claimed in claim 7, it is characterized in that the mixture heated melt temperature is 60～85 ℃, mixing time is 10～30 minutes, dripping the system temperature and be 60～85 ℃, dropper bore is 1.1～3.5 millimeters, and condensing agent is 0～18 ℃ liquid paraffin or a methyl-silicone oil.
9, the preparation method of treatment bronchitis medication medication as claimed in claim 8 is characterized in that the mixture heated melt temperature is 64 ℃, and dripping a system temperature and be 64 ℃, dropper bore is 1.2～2.5 millimeters, and condensing agent is 0 ℃ a methyl-silicone oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510013617A CN100592907C (en) | 2005-06-01 | 2005-06-01 | Medication doe treating bronchitis, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510013617A CN100592907C (en) | 2005-06-01 | 2005-06-01 | Medication doe treating bronchitis, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872035A true CN1872035A (en) | 2006-12-06 |
| CN100592907C CN100592907C (en) | 2010-03-03 |
Family
ID=37482746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510013617A Expired - Fee Related CN100592907C (en) | 2005-06-01 | 2005-06-01 | Medication doe treating bronchitis, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100592907C (en) |
-
2005
- 2005-06-01 CN CN200510013617A patent/CN100592907C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100592907C (en) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1626143A (en) | Medication for treating pharyngitis | |
| CN1872327A (en) | Composition of medicine for treating diarrhea | |
| CN1872139A (en) | Drop pills for treating bronchitis | |
| CN1626145A (en) | Medication for treating cough | |
| CN1872035A (en) | Medication doe treating bronchitis, and preparation method | |
| CN1872124A (en) | Medicine for treating bronchitis | |
| CN1872052A (en) | Drop pills of simvastatin, and preparation method | |
| CN1626124A (en) | Drop pills of medical broth of small bupleurum root | |
| CN1872318A (en) | Drop pills of oil of zedoary turmeric, and preparation method | |
| CN1872036A (en) | Drop pills of agrimophol, and preparation method | |
| CN1626136A (en) | Medication for treating bronchitis | |
| CN1872050A (en) | Drop pills of silymarin, and preparation method | |
| CN1626135A (en) | Medication for treating cough and gasp | |
| CN1872259A (en) | Composition of medicine for treating coronary heart disease | |
| CN1626137A (en) | Medication for treating bronchitis | |
| CN1872137A (en) | Drop pills of total glycoside of Jiaogulan, and preparation method | |
| CN1872053A (en) | Drop pills of daphnetin, and preparation method | |
| CN1872184A (en) | Drop pills of reducing blood fat and preparation method | |
| CN1872044A (en) | Medication for treating coronary heart disease | |
| CN1872108A (en) | Drop pills of centella total glycoside, and preparation method | |
| CN1872054A (en) | Drop pills of coumarin acetic acid, and preparation method | |
| CN1872076A (en) | Drop pills of cucurbitacine, and preparation method | |
| CN1872077A (en) | Medicine for treating cardiac insufficiency | |
| CN1872112A (en) | Drop pills of total saponin of gen-seng haulms, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100303 Termination date: 20190601 |